Standard BioTools Inc. (NASDAQ: LAB) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 31.10% | Shs Outstand | 391.46M | Perf Week | 11.57% |
| Market Cap | 301.35M | Forward P/E | - | EPS next Y | -0.16 | Insider Trans | 0.00% | Shs Float | 42.77M | Perf Month | 14.62% |
| Enterprise Value | 28.17M | PEG | - | EPS next Q | -0.02 | Inst Own | - | Short Float | 0.76% | Perf Quarter | -7.22% |
| Income | -88.00M | P/S | 3.55 | EPS this Y | 56.52% | Inst Trans | - | Short Ratio | 0.90 | Perf Half Y | -19.81% |
| Sales | 85.00M | P/B | 0.56 | EPS next Y | -60.00% | ROA | -13.93% | Short Interest | 2.98M | Perf YTD | -39.86% |
| Book/sh | 1.38 | P/C | 0.63 | EPS next 5Y | - | ROE | -18.16% | 52W High | 1.72 -55.24% | Perf Year | -42.98% |
| Cash/sh | 1.22 | P/FCF | - | EPS past 3/5Y | - | ROIC | -8.25% | 52W Low | 0.63 23.15% | Perf 3Y | -73.36% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -4.63% -9.24% | Gross Margin | 49.14% | Volatility | 5.56% 5.82% | Perf 5Y | -88.68% |
| Dividend TTM | - | EV/Sales | 0.33 | EPS Y/Y TTM | 55.77% | Oper. Margin | -94.80% | ATR (14) | 0.04 | Perf 10Y | -91.35% |
| Dividend Ex-Date | - | Quick Ratio | 8.80 | Sales Y/Y TTM | -51.15% | Profit Margin | -103.29% | RSI (14) | 61.42 | Recom | 2.40 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.10 | EPS Q/Q | - | SMA20 | 12.77% | Beta | 1.37 | Target Price | 3.25 |
| Payout | 0.00% | Debt/Eq | 0.07 | Sales Q/Q | -9.09% | SMA50 | 1.59% | Rel Volume | 1.00 | Prev Close | 0.73 |
| Employees | 387 | LT Debt/Eq | 0.06 | Earnings | Nov 03 | SMA200 | -25.41% | Avg Volume | 2.70M | Price | 0.77 |
| IPO Date | Feb 10, 2011 | Option/Short | No / No | EPS/Sales Surpr. | -449.02% -3.37% | Net Debt/EBITDA | 2.63 | Volume | 2,694,878 | Change | 5.45% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-27-25 | Downgrade | Keybanc | Overweight → Sector Weight | |
| Apr-04-24 | Reiterated | Jefferies | ||
| Nov-05-19 | Downgrade | Janney Montgomery Scott | Buy → Neutral | |
| Oct-17-19 | Upgrade | UBS | Neutral → Buy | |
| Jan-02-19 | Upgrade | Janney Montgomery Scott | Neutral → Buy | |
| Nov-01-18 | Upgrade | Piper Sandler | Neutral → Overweight | |
| Feb-04-16 | Upgrade | Mizuho | Neutral → Buy | |
| Jan-19-16 | Downgrade | Cowen & Co. | Outperform → Market Perform | |
| Nov-01-15 | Upgrade | Cantor Fitzgerald | Hold → Buy | |
| Oct-29-15 | Upgrade | Cantor Fitzgerald | Hold → Buy |
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 85 | 85 | 174 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 44 | 43 | 90 | — | — | — | — | — | — | |
| Gross Profit | 41 | 43 | 84 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 86 | 110 | 157 | — | — | — | — | — | — | |
| Research and Development | 18 | 26 | 62 | — | — | — | — | — | — | |
| Other Operating Expense | 18 | 0 | 40 | — | — | — | — | — | — | |
| Operating Income | -79 | -93 | -175 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -10 | -3 | 40 | — | — | — | — | — | — | |
| Net Income Before Taxes | -91 | -97 | -138 | — | — | — | — | — | — | |
| Income Taxes | -37 | -38 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -88 | -75 | -139 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -55 | -59 | -139 | — | — | — | — | — | — | |
| Net Income | -88 | -75 | -139 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.23 | -0.20 | -0.52 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.23 | -0.20 | -0.52 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.23 | -0.20 | -0.52 | — | — | — | — | — | — | |
| EBITDA | -92 | -90 | -118 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.54 | 5.75 | 3.55 | — | — | — | — | — | — | |
| Gross Margin | 48.24 | 50.59 | 48.28 | — | — | — | — | — | — | |
| Operating Margin | -92.94 | -109.41 | -100.57 | — | — | — | — | — | — | |
| Net Margin | -103.53 | -88.24 | -79.89 | — | — | — | — | — | — | |
| Shares Outstanding | 391 | 382 | 353 | — | — | — | — | — | — | |
| Market Capitalization | 301 | 489 | 618 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Egholm Michael | President & CEO | Apr 06 '26 | Option Exercise | 0.00 | 196,513 | 0 | 6,790,596 | Apr 08 |
| Kim Hanjoon Alex | Chief Financial Officer | Apr 06 '26 | Option Exercise | 0.00 | 70,183 | 0 | 2,800,702 | Apr 08 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Dec 04 '25 | Buy | 1.45 | 150,000 | 217,020 | 72,100,000 | Dec 04 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Dec 03 '25 | Buy | 1.44 | 75,000 | 108,037 | 71,950,000 | Dec 04 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Dec 02 '25 | Buy | 1.42 | 125,000 | 177,513 | 71,875,000 | Dec 04 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 25 '25 | Buy | 1.30 | 7,550,000 | 9,838,405 | 71,750,000 | Nov 26 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 24 '25 | Buy | 1.43 | 150,000 | 214,875 | 64,200,000 | Nov 26 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 20 '25 | Buy | 1.30 | 450,000 | 586,260 | 64,050,000 | Nov 20 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 19 '25 | Buy | 1.28 | 350,000 | 448,910 | 63,600,000 | Nov 20 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 18 '25 | Buy | 1.23 | 275,000 | 339,405 | 63,250,000 | Nov 20 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 17 '25 | Buy | 1.22 | 225,000 | 275,580 | 62,975,000 | Nov 17 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 14 '25 | Buy | 1.24 | 250,000 | 309,800 | 62,750,000 | Nov 17 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 13 '25 | Buy | 1.20 | 450,000 | 541,395 | 62,500,000 | Nov 17 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 12 '25 | Buy | 1.19 | 375,000 | 445,838 | 62,050,000 | Nov 12 |
| Casdin Partners Master Fund, L.P. | director, 10 percent owner: | Nov 11 '25 | Buy | 1.20 | 300,000 | 358,800 | 61,675,000 | Nov 12 |